Pediatric Nephrology

, Volume 27, Issue 3, pp 357–362

Dyslipidemia in children with CKD: should we treat with statins?

Educational Review

Abstract

Dyslipidemia has been shown to be a risk factor for increased cardiovascular morbidity and mortality in adult patients with chronic kidney disease (CKD) stages 2–4. In patients on dialysis, a paradoxical correlation has been found between low cholesterol values and increased mortality rates. No data exist in children. Treatment with statins has been convincingly shown to both reduce blood lipid levels and mortality rates from cardiovascular disease in adult patients in CKD stages 2–4. There is no strong literature support for treating patients on dialysis or after having had a transplant. Data on benefits of statin therapy do not exist in children with CKD. There are many differences between adult and paediatric kidney patients, and I caution on extrapolating the findings in adult patients to children. Studies are thus needed to evaluate the benefits and potential problems of statin treatment in children with CKD.

Keywords

Lipids Cholesterol Chronic kidney disease Cardiovascular disease Children 

Reference

  1. 1.
    Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112–S119PubMedCrossRefGoogle Scholar
  2. 2.
    Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL, Goldsmith DJ (2010) Vascular calcification in chronic kidney disease. Clin Sci (Lond) 119:111–121CrossRefGoogle Scholar
  3. 3.
    Querfeld U (2004) The clinical significance of vascular calcification in young patients with end-stage renal disease. Pediatr Nephrol 19:478–484PubMedCrossRefGoogle Scholar
  4. 4.
    Muntner P, He J, Astor BC, Folsom AR, Coresh J (2005) Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16:529–538PubMedCrossRefGoogle Scholar
  5. 5.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRefGoogle Scholar
  6. 6.
    Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081PubMedCrossRefGoogle Scholar
  7. 7.
    Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483PubMedCrossRefGoogle Scholar
  8. 8.
    Lilien MR, Groothoff JW (2009) Cardiovascular disease in children with CKD or ESRD. Nat Rev Nephrol 5:229–235PubMedCrossRefGoogle Scholar
  9. 9.
    Groothoff JW, Lilien MR, van de Kar NC, Wolff ED, Davin JC (2005) Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatr Nephrol 20:374–379PubMedCrossRefGoogle Scholar
  10. 10.
    Hruska KA, Choi ET, Memon I, Davis TK, Mathew S (2010) Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 25:769–778PubMedCrossRefGoogle Scholar
  11. 11.
    Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr K, Jobs K, Grenda R, Wawer ZT, Rajszys P, Troger J, Mehls O, Schaefer F (2005) Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 16:1494–1500PubMedCrossRefGoogle Scholar
  12. 12.
    Wilson AC, Mitsnefes MM (2009) Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis 54:345–360PubMedCrossRefGoogle Scholar
  13. 13.
    Kwan BC, Kronenberg F, Beddhu S, Cheung AK (2007) Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18:1246–1261PubMedCrossRefGoogle Scholar
  14. 14.
    Iseki K, Yamazato M, Tozawa M, Takishita S (2002) Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61:1887–1893PubMedCrossRefGoogle Scholar
  15. 15.
    Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P (2008) Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 21:635–644PubMedGoogle Scholar
  16. 16.
    Baigent C, Landray MJ, Wheeler DC (2007) Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Semin Dial 20:498–503PubMedCrossRefGoogle Scholar
  17. 17.
    Querfeld U (1993) Disturbances of lipid metabolism in children with chronic renal failure. Pediatr Nephrol 7:749–757PubMedCrossRefGoogle Scholar
  18. 18.
    Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC, Warady BA, Furth SL (2010) Dyslipidemia in children with chronic kidney disease. Kidney Int 78:1154–1163PubMedCrossRefGoogle Scholar
  19. 19.
    Silverstein DM, Palmer J, Polinsky MS, Braas C, Conley SB, Baluarte HJ (2000) Risk factors for hyperlipidemia in long-term pediatric renal transplant recipients. Pediatr Nephrol 14:105–110PubMedCrossRefGoogle Scholar
  20. 20.
    Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338:b2376PubMedCrossRefGoogle Scholar
  21. 21.
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373:1175–1182PubMedCrossRefGoogle Scholar
  22. 22.
    de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ (2002) Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 106:2231–2237PubMedCrossRefGoogle Scholar
  23. 23.
    Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, Sijbrands EJ, Kastelein JJ (2004) Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292:331–337PubMedCrossRefGoogle Scholar
  24. 24.
    Daniels SR, Greer FR (2008) Lipid screening and cardiovascular health in childhood. Pediatrics 122:198–208PubMedCrossRefGoogle Scholar
  25. 25.
    de Ferranti S, Ludwig DS (2008) Storm over statins–the controversy surrounding pharmacologic treatment of children. N Engl J Med 359:1309–1312PubMedCrossRefGoogle Scholar
  26. 26.
    Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G (2003) Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138:98–104PubMedGoogle Scholar
  27. 27.
    Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557–1563PubMedCrossRefGoogle Scholar
  28. 28.
    Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J (2007) The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 117:64–74PubMedCrossRefGoogle Scholar
  29. 29.
    Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC (2008) Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336:645–651PubMedCrossRefGoogle Scholar
  30. 30.
    Stegmayr BG, Brannstrom M, Bucht S, Crougneau V, Dimeny E, Ekspong A, Eriksson M, Granroth B, Grontoft KC, Hadimeri H, Holmberg B, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Stenlund H, Wikdahl AM (2005) Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol 39:489–497PubMedCrossRefGoogle Scholar
  31. 31.
    Sharp Collaborative Group (2010) Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 160:785–794PubMedCrossRefGoogle Scholar
  32. 32.
    Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297–304PubMedCrossRefGoogle Scholar
  33. 33.
    Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW (2005) HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119–126PubMedCrossRefGoogle Scholar
  34. 34.
    Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248PubMedCrossRefGoogle Scholar
  35. 35.
    Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407PubMedCrossRefGoogle Scholar
  36. 36.
    Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361:2024–2031PubMedCrossRefGoogle Scholar
  37. 37.
    Holdaas H, Fellstrom B, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Logan JO, Staffler B, Gimpelewicz C (2005) Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20:974–980PubMedCrossRefGoogle Scholar
  38. 38.
    Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P, Bojorquez-Ochoa A, Maya ER, Perez-Martinez MP (2009) Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. Pediatr Nephrol 24:1205–1210PubMedCrossRefGoogle Scholar
  39. 39.
    Butani L (2005) Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation. Pediatr Transplant 9:746–753PubMedCrossRefGoogle Scholar
  40. 40.
    Mahle WT, Vincent RN, Berg AM, Kanter KR (2005) Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant 24:63–66PubMedCrossRefGoogle Scholar
  41. 41.
    Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA (2007) A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 27:1803–1810PubMedCrossRefGoogle Scholar
  42. 42.
    Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006–2016PubMedCrossRefGoogle Scholar
  43. 43.
    Huskey J, Lindenfeld J, Cook T, Targher G, Kendrick J, Kjekshus J, Pedersen T, Chonchol M (2009) Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4 S). Atherosclerosis 205:202–206PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  1. 1.Paediatric NephrologistGreat Ormond Street Hospital for ChildrenLondonUK

Personalised recommendations